Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer

´ëÇѺ´¸®ÇÐȸÁö 2012³â 46±Ç 5È£ p.470 ~ 477
ÀÌÈ£¿ø, ±èÀ§ÇÑ, ¿À¹ÌÇý,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÈ£¿ø ( Lee Ho-Won ) 
Soonchunhyang University College of Medicine Department of Pathology

±èÀ§ÇÑ ( Kim Eui-Han ) 
Soonchunhyang University College of Medicine Department of Pathology
¿À¹ÌÇý ( Oh Mee-Hye ) 
Soonchunhyang University College of Medicine Department of Pathology

Abstract


Background : Ezrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs).

Methods : Immunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis.

Results : The ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p= 0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC.

Conclusions : Ezrin might be a molecular marker to predict poor prognosis of NSCLC.

Å°¿öµå

Carcinoma; non-small cell lung; Ezrin; Prognosis

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS